Beam Therapeutics SVP Bethany J. Cavanagh Sells 6,198 Shares for $216,933
ByAinvest
Sunday, Feb 1, 2026 4:12 am ET1min read
BEAM--
Bethany J. Cavanagh, Senior Vice President of Finance and Treasurer at Beam Therapeutics, sold 6,198 shares for $216,933 at a weighted average price of $35.00 per share. The sale represented 15.11% of her direct holdings, reducing her direct ownership to 34,813 shares. Beam Therapeutics is a biotechnology company specializing in gene editing therapies, and the sale was part of a Rule 10b5-1 trading plan. The company's medicines aim to advance beyond clinical trials and receive FDA approval.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet